补肺消痿汤联合阿帕替尼治疗晚期肺癌的临床疗效及对CEA、SCC及CA125的影响

Clinical Effect of Bufei Xiaowei Decoction(补肺消痿汤)Combined with Apatinib on Advanced Lung Cancer and Its Effect on CEA,SCC and CA125

目的探讨补肺消痿汤联合阿帕替尼治疗晚期肺癌的临床疗效及对CEA、SCC及CA125的影响。方法选择2016年6月—2020年5月南京中医药大学连云港附属医院及徐州市中医院收治的晚期肺癌患者120例,依据随机对照法将患者分为研究组和对照组,每组60例。对照组患者口服甲磺酸阿帕替尼治疗,500 mg/次,1次/d,连续治疗4周。研究组在对照组治疗的基础上,口服补肺消痿汤治疗。连续治疗4周。比较两组治疗疗效,治疗前后肿瘤标志物癌胚抗原(carcino-embryonic antigen, CEA)、鳞状细胞癌抗原(squamouscellcarcinomaantigen, SCC)、糖链抗原125 (carbohydrate antigen 125, CA125)水平,比较两组治疗前后恶性肿瘤患者生活质量核心问卷(QLQ-C30)以及治疗过程中发生的不良反应。结果研究组治疗总有效率高于对照组(P<0.05);研究组治疗后神疲乏力、胸脘痞闷、恶心呕吐等中医证候积分低于对照组(P<0.05);研究组治疗后肿瘤标志物CEA、SCC及CA125水平低于对照组(P<0.05);研究组治疗后QLQ-C30评分高于对照组(P<0.05);研究组患者不良反应总发生率低于对照组(P<0.05)。结论补肺消痿汤结合阿帕替尼治疗晚期肺癌疗效确切,可有效的改善患者的临床症状,降低肿瘤标志物CEA、SCC、CA125的水平,提高治疗疗效,降低机体不良反应,提高患者的生活质量,减轻痛苦,有广阔的应用前景。

Objective To explore the clinical effect of Bufei Xiaowei Decoction(补肺消痿汤) combined with apatinib in the treatment of advanced lung cancer and its effect on CEA, SCC and CA125. Methods A total of 120 patients with advanced lung cancer admitted to Lianyungang Affiliated Hospital of Nanjing University of Traditional Chinese Medicine from June 2016 to May 2020 were selected. Based on randomized controlled method, the patients were divided into the study group and the control group, 60 cases in each group. Patients in the control group were treated with oral apatinib mesylate, 500 mg/times, 1/d, continuously for 4 weeks. The study group was treated with Bufei Xiaowei Decoction on the basis of the control group. The treatment lasted for 4 weeks. The therapeutic effect, TCM symptom scores, levels of CEA, SCC and CA125, QLQ-C30 scores and adverse reactions were compared before and after treatment. Results The study group’s total effective rate was higher than that of the control group(P<0.05). After treatment, the TCM symptom scores of mental fatigue, chest congestion, nausea and vomiting and pulse string slippage were lower than those of the control group(P<0.05). After treatment, the control group’s levels of CEA, SCC and CA125 were lower than those of the control group(P<0.05). The team life quality score was higher than that of the control group after treatment(P<0.05). The total incidence of adverse reactions in the study group was lower than that in the control group(P<0.05). Conclusion The effect of Bufei Xiaowei Decoction combined with apatinib in the treatment of advanced lung cancer is definite, and can reduce levels of tumor markers CEA, SCC and CA125, improve the curative effect, reduce adverse reaction, improve the quality of life of patients and alleviate pain. The treatment has broad application prospects.